WAVEGATE NEWS

WAVEGATE CORPORATION | NEWS

May 4, 2026

Statement Regarding the December 2024 Series A Funding Announcement

Lake Charles,  LA — February 2, 2026 — Wavegate Corporation, a clinical-stage neuromodulation company advancing next-generation spinal cord stimulation (SCS) technologies, today announced the appointment of Jeff Cambra as Chief Executive Officer.

Mr. Cambra brings more than 28 years of executive leadership experience across medical devices, neuroscience, drug-device combination products, and complex regulated healthcare markets. He has held senior C-level roles spanning general management, commercial strategy, business development, operations, and fundraising, with a proven track record of scaling organizations through pivotal inflection points.

“Jeff is exactly the type of seasoned MedTech leader Wavegate needs as we enter our next phase of growth,” said Erich W. Wolf II, MD, PhD, Founder of Wavegate Corporation. “His depth of experience in building and commercializing complex medical technologies, coupled with his strategic and operational discipline, positions Wavegate to execute decisively as we advance toward clinical and regulatory milestones.”

As CEO, Mr. Cambra will lead Wavegate’s corporate…

LAKE CHARLES, La., Jan. 13, 2022 /PRNewswire/ -- Wavegate Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its StimuLux™ optical reflectometry system for closed-loop adaptive modulation of spinal cord stimulation. The FDA's Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary evidence must demonstrate a reasonable expectation that the device will provide improved effectiveness compared to the standard of care.

"We are pleased the FDA has granted Breakthrough Device designation for our novel StimuLux™ technology. This underscores the urgent need within our society for more effective treatments of chronic, debilitating pain," said Erich Wolf, MD, PhD, Chief Executive Officer. "We are eager to closely collaborate with the FDA as Wavegate works toward advancing the state of the art."

StimuLux™ is a…

April 23, 2020- Lake Charles, LA. Wavegate Technologies, LLC, has been restructured as a Delaware C-corporation. This gives Wavegate Corporation additional flexibility in stock offerings to investors and provides a widely-accepted legal framework under Delaware law.

Wavegate is pleased to announce that Matt F. Thomas has joined Wavegate's Board of Directors. Matt brings deep domain experience to Wavegate, having served as the General Manager for Medtronic's Spinal Cord Stimulation business. Matt is a welcome addition to the senior management team at Wavegate and rounds out the executive experience required to navigate Wavegate's Ellipse platform to the best-in-class market leader.

Matt Thomas has over 25 years of experience leading medical device businesses. He has broad experience in strategy, business development, marketing, sales & new product development. Prior to joining Cerapedics in 2020, Matt was Vice President & General Manager for Medtronic’s Spinal Cord Stimulation & Early Interventions pain business. Previously, Matt also led a turnaround of Medtronic’s Kyphon business, returning it to growth for the first time since the acquisition. He joined Medtronic in 2002 and also had leadership roles in spine, diabetes, and deep brain stimulat…